Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Cardiovascular Actions of Incretin-Based Therapies
John R. Ussher, Daniel J. Drucker
Circulation Research (2014) Vol. 114, Iss. 11, pp. 1788-1803
Open Access | Times Cited: 318

Showing 1-25 of 318 citing articles:

Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Steven P. Marso, Gilbert H. Daniels, Kirstine Brown‐Frandsen, et al.
New England Journal of Medicine (2016) Vol. 375, Iss. 4, pp. 311-322
Open Access | Times Cited: 5997
Glucagon-like peptide 1 (GLP-1)
Timo D. Müller, Brian Finan, Stephen R. Bloom, et al.
Molecular Metabolism (2019) Vol. 30, pp. 72-130
Open Access | Times Cited: 1306
Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1
Daniel J. Drucker
Cell Metabolism (2018) Vol. 27, Iss. 4, pp. 740-756
Open Access | Times Cited: 1241
Effects of Liraglutide on Clinical Stability Among Patients With Advanced Heart Failure and Reduced Ejection Fraction
Kenneth B. Margulies, Adrian F. Hernandez, Margaret M. Redfield, et al.
JAMA (2016) Vol. 316, Iss. 5, pp. 500-500
Open Access | Times Cited: 536
Pharmacology, Physiology, and Mechanisms of Action of Dipeptidyl Peptidase-4 Inhibitors
Erin E. Mulvihill, Daniel J. Drucker
Endocrine Reviews (2014) Vol. 35, Iss. 6, pp. 992-1019
Open Access | Times Cited: 528
The Cardiovascular Biology of Glucagon-like Peptide-1
Daniel J. Drucker
Cell Metabolism (2016) Vol. 24, Iss. 1, pp. 15-30
Open Access | Times Cited: 522
Cardiovascular Actions and Clinical Outcomes With Glucagon-Like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors
Michael A. Nauck, Juris J. Meier, Matthew A. Cavender, et al.
Circulation (2017) Vol. 136, Iss. 9, pp. 849-870
Open Access | Times Cited: 498
Effect of liraglutide, a glucagon‐like peptide‐1 analogue, on left ventricular function in stable chronic heart failure patients with and without diabetes (LIVE)—a multicentre, double‐blind, randomised, placebo‐controlled trial
Anders Jorsal, Caroline Kistorp, Pernille Holmager, et al.
European Journal of Heart Failure (2016) Vol. 19, Iss. 1, pp. 69-77
Open Access | Times Cited: 425
Comprehensive Management of Cardiovascular Risk Factors for Adults With Type 2 Diabetes: A Scientific Statement From the American Heart Association
Joshua J. Joseph, Prakash Deedwania, Tushar Acharya, et al.
Circulation (2022) Vol. 145, Iss. 9
Open Access | Times Cited: 376
The GLP-1 Analogs Liraglutide and Semaglutide Reduce Atherosclerosis in ApoE−/− and LDLr−/− Mice by a Mechanism That Includes Inflammatory Pathways
Günaj Rakipovski, Bidda Rolin, Jane Nøhr, et al.
JACC Basic to Translational Science (2018) Vol. 3, Iss. 6, pp. 844-857
Open Access | Times Cited: 339
Glucagon-Like Peptide-1 and Its Class B G Protein–Coupled Receptors: A Long March to Therapeutic Successes
Chris de Graaf, Dan Donnelly, Denise Wootten, et al.
Pharmacological Reviews (2016) Vol. 68, Iss. 4, pp. 954-1013
Open Access | Times Cited: 319
Diabetic cardiomyopathy - A comprehensive updated review
Ghulam Murtaza, Hafeez Ul Hassan Virk, Muhammad Khalid, et al.
Progress in Cardiovascular Diseases (2019) Vol. 62, Iss. 4, pp. 315-326
Closed Access | Times Cited: 272
Cardiovascular Effects of New Oral Glucose-Lowering Agents
André Scheen
Circulation Research (2018) Vol. 122, Iss. 10, pp. 1439-1459
Open Access | Times Cited: 251
Islet α cells and glucagon—critical regulators of energy homeostasis
Jonathan E. Campbell, Daniel J. Drucker
Nature Reviews Endocrinology (2015) Vol. 11, Iss. 6, pp. 329-338
Closed Access | Times Cited: 244
Contrasting Effects of Lixisenatide and Liraglutide on Postprandial Glycemic Control, Gastric Emptying, and Safety Parameters in Patients With Type 2 Diabetes on Optimized Insulin Glargine With or Without Metformin: A Randomized, Open-Label Trial
Juris J. Meier, Julio Rosenstock, Agnès Hincelin-Méry, et al.
Diabetes Care (2015) Vol. 38, Iss. 7, pp. 1263-1273
Open Access | Times Cited: 239
Glucagon-like peptide 1 receptor agonists: cardiovascular benefits and mechanisms of action
John R. Ussher, Daniel J. Drucker
Nature Reviews Cardiology (2023) Vol. 20, Iss. 7, pp. 463-474
Closed Access | Times Cited: 215
GLP-1 Receptor Expression Within the Human Heart
Laurie L. Baggio, Bernardo Yusta, Erin E. Mulvihill, et al.
Endocrinology (2018) Vol. 159, Iss. 4, pp. 1570-1584
Open Access | Times Cited: 213
Exenatide decreases liver fat content and epicardial adipose tissue in patients with obesity and type 2 diabetes: a prospective randomized clinical trial using magnetic resonance imaging and spectroscopy
Anne Dutour, Inès Abdesselam, Patricia Ancel, et al.
Diabetes Obesity and Metabolism (2016) Vol. 18, Iss. 9, pp. 882-891
Closed Access | Times Cited: 210
Endothelial GLP-1 (Glucagon-Like Peptide-1) Receptor Mediates Cardiovascular Protection by Liraglutide In Mice With Experimental Arterial Hypertension
Johanna Helmstädter, Katie Frenis, Konstantina Filippou, et al.
Arteriosclerosis Thrombosis and Vascular Biology (2019) Vol. 40, Iss. 1, pp. 145-158
Open Access | Times Cited: 180
The Role of DPP-4 Inhibitors in the Treatment Algorithm of Type 2 Diabetes Mellitus: When to Select, What to Expect
Konstantinos Makrilakis
International Journal of Environmental Research and Public Health (2019) Vol. 16, Iss. 15, pp. 2720-2720
Open Access | Times Cited: 159
The effects of liraglutide and dapagliflozin on cardiac function and structure in a multi-hit mouse model of heart failure with preserved ejection fraction
Coenraad Withaar, Laura M G Meems, George Markousis‐Mavrogenis, et al.
Cardiovascular Research (2020) Vol. 117, Iss. 9, pp. 2108-2124
Open Access | Times Cited: 159
The anti-inflammatory and immunological properties of GLP-1 Receptor Agonists
Giulia Bendotti, Laura Montefusco, Maria Elena Lunati, et al.
Pharmacological Research (2022) Vol. 182, pp. 106320-106320
Closed Access | Times Cited: 147
Metabolic remodelling in atrial fibrillation: manifestations, mechanisms and clinical implications
David Bode, Julius Ryan D. Pronto, Gabriele G. Schiattarella, et al.
Nature Reviews Cardiology (2024) Vol. 21, Iss. 10, pp. 682-700
Closed Access | Times Cited: 16
Effects of Glucagon-Like Peptide 1 Receptor Agonists on Atrial Fibrillation Recurrence After Catheter Ablation: A Systematic Review and Meta-analysis
Paschalis Karakasis, Nikolaos Fragakis, Dimitrios Patoulias, et al.
Advances in Therapy (2024) Vol. 41, Iss. 10, pp. 3749-3756
Closed Access | Times Cited: 16
GLP-1 stimulates insulin secretion by PKC-dependent TRPM4 and TRPM5 activation
Makoto Shigeto, Reshma Ramracheya, Andrei I. Tarasov, et al.
Journal of Clinical Investigation (2015) Vol. 125, Iss. 12, pp. 4714-4728
Open Access | Times Cited: 167
Page 1 - Next Page

Scroll to top